Clinical Trial Details


Research Study Summary

A randomised, double-blind, placebo-controlled, proof-of concept, dose-ranging study of BI 655066 in patients with active psoriatic arthritis.


Psoriatic arthritis is a chronic inflammatory disease which can affect any joint in your body. Psoriatic arthritis usually develops in people who have psoriasis, a disease in which scaly red and white patches develop on the skin. Both psoriasis and psoriatic arthritis are caused by an overactive immune system where healthy body tissue is attacked by mistake. This study will look at a new investigational drug, BI 655066, and provide proof-of-concept and dose-ranging data of BI 655066 in patients with active psoriatic arthritis.

To Learn more

CW ID: 216053
Date Last Changed: June 14, 2016

Clinical Trial Snapshot

Both Male and Female
18 and up
Overall Status
Lead Sponsor
Boehringer Ingelheim
16 Weeks
Facility Type


Inclusion Criteria:
  • Have psoriatic arthritis (PsA) symptoms for ≥ 6 months prior to screening
  • Have PsA on the basis of the Classification Criteria for Psoriatic Arthritis (CASPAR) with peripheral symptoms
  • Have ≥5 tender joints and ≥5 swollen joints at screening


Michelle Orzechowski
University of South Florida - Morsani Center for Advanced Healthcare
13330 USF Laurel Drive
Tampa, FL 33612
Phone: 813-974-2473

View Map

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.